<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220622</url>
  </required_header>
  <id_info>
    <org_study_id>BSP-SOP-040</org_study_id>
    <nct_id>NCT01220622</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes</brief_title>
  <acronym>NICE</acronym>
  <official_title>Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Science and Technology of the People´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Science and Technology of the People´s Republic of China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial was designed to test the hypothesis that early treatment with nimodipine has a
      positive effect on cognition impairment after acute ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      656 patients diagnosed with acute cerebral ischemia disease (onset≤7d) based on ICD-10 and
      CT/MRI criteria, who have cognitive impairment meeting all of the inclusion criteria and none
      of the exclusion criteria, will be included and randomized into nimodipine treatment group
      and the controlled group.Evaluations of cognitive function will be taken at baseline, 1
      month, 3 months, and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the effect of nimodipine on the cognitive function after acute cerebral ischemia with ADAS-cog and MMSE at 6 months in the ITT population</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the effect of nimodipine on the cognitive function after acute cerebral ischemia with MoCA and FAB at 6 months in the ITT population</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prevalence of possible vascular dementia diagnosed by NINDS-AIREN criteria at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effect of nimodipine on the cognitive function after acute cerebral ischemia with ADAS-cog and MMSE at 3 months in the ITT population</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effect of nimodipine on the cognitive function after acute cerebral ischemia with MoCA and FAB at 3 months in the ITT population</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prevalence of possible vascular dementia diagnosed by NINDS-AIREN criteria at 1 month</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prevalence of possible vascular dementia diagnosed by NINDS-AIREN criteria at 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">656</enrollment>
  <condition>Stroke</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Nimodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimodipine</intervention_name>
    <description>Administration of nimodipine 30mg tid for 6 months</description>
    <arm_group_label>Nimodipine</arm_group_label>
    <other_name>Nimodiping Pian</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of placebo 30mg tid for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Subjects between 30 and 80 years.

          -  2. ICD-10 and CT/MRI criteria for acute cerebral infarction.

          -  3. Stroke within 7 days after onset.

          -  4.based on years of education correction.MMSE＞17(illiteracy),MMSE＞20(primary
             school),MMSE＞24(others)

          -  5. MoCA≤26 at baseline.

          -  6.Hachinski ischemic score ≥7 at baseline.

          -  7.Expected good compliance to study.

          -  8.Informed consent signed.

        Exclusion Criteria:

          -  1.Diagnosis of schizophrenia, major anxiety syndrome, major depression.

          -  2.Alzheimer disease, Parkinson disease, Huntington disease, and fronto-temporal
             dementia.

          -  3.Dementia caused by (e.g., central nervous system trauma, tumor, infections,
             metabolic disorders, normal pressure hydrocephalus, lack of folic acid or vitamin B12,
             or thyroid hormone deficiency).

          -  4.Contraindications to dihydropyridine derivatives.

          -  5.Aphasia or other diseases that affect cognitive evaluation.

          -  6.Serious arrhythmias, bradycardia (&lt;50 bpm) or tachycardia (&gt;120 bpm); myocardial
             infarction within the past 6 months; blood pressure &lt;90/60mmHg; severe renal or
             hepatic insufficiency; severe anemia, Hb&lt;100g/L; severe gastrointestinal disorders;
             tumor.

          -  7.History of epilepsy, use of the antiepileptic drugs.

          -  8.CT/MRI showed neurodegenerative changes or other lesions except cerebral ischemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang Yongjun, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tian Tan Hospital, Capital Medical University, Beijing, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng tao, M.D.</last_name>
    <phone>00861067098343</phone>
    <email>happyft@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wang xuemei, M.D.</last_name>
    <email>minnie_wxm@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tian Tan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng tao, M.D.</last_name>
      <phone>00861067098343</phone>
      <email>happyft@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Wang xuemei, M.D.</last_name>
      <email>minnie_wxm@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2010</study_first_submitted>
  <study_first_submitted_qc>October 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2010</study_first_posted>
  <last_update_submitted>October 13, 2010</last_update_submitted>
  <last_update_submitted_qc>October 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Yongjun Wang</name_title>
    <organization>Beijing Tian Tan Hospital, Capital Medical University, China</organization>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Mild cognitive impairment</keyword>
  <keyword>Nimodipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

